Search the Newsreel

Empowered Funds LLC Buys 119,202 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

Empowered Funds LLC significantly increased its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 661.6% in the first quarter, adding 119,202 shares to reach a total of 137,220 shares valued at $8.6 million. This move is part of a broader trend of institutional investment, with …

Handelsbanken Fonder AB Buys New Shares in James Hardie Industries PLC. $JHX

IONS Stock Jumps 4% After-Hours — Goldman Sachs Lifts Price Target On Tryngolza Approval

Bank of America Corp DE Purchases 45,220 Shares of Texas Capital Bancshares, Inc. $TCBI

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Consensus Rating of "Moderate Buy" from Analysts

NRx Pharmaceuticals (NASDAQ:NRXP) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $34.50. Despite this, the company recently missed its quarterly earnings and revenue estimates. Hedge funds and institutional investors hold 4.27% of the stock.

Bank of America Corp DE Boosts Stake in Kiniksa Pharmaceuticals International, plc $KNSA

Handelsbanken Fonder AB Increases Stock Position in Charles River Laboratories International, Inc. $CRL

Handelsbanken Fonder AB increased its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 36.9% in the second quarter, now owning 19,306 shares valued at $4.38 million. This comes as the company reported strong quarterly earnings, beating estimates with an EPS of $3.02, though …

National Energy Services Reunited (NESR), Why Is It Back In The Spotlight?

National Energy Services Reunited (NESR) is gaining attention after strong Q2 2026 earnings, increased sales, and new contracts in the Middle East. The company's stock price has shown significant momentum, with a 90-day return of 42.62%. While a valuation model suggests the stock is …

Connect Biopharma (NASDAQ:CNTB) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen has upgraded Connect Biopharma (NASDAQ:CNTB) from a "sell" to a "hold" rating, though the broader analyst consensus remains a "Moderate Buy" with an average price target of $7.43. The company recently reported a quarterly loss of $0.27 per share, outperforming expectations, …

Vertex (VRTX) Stock Looks Above Fair Value On Earnings Yet About Right Overall

Vertex Pharmaceuticals (VRTX) has seen strong multi-year performance, with a 158.2% return over the past five years, but its current valuation suggests it's neither a clear bargain nor obviously overvalued. The stock trades at 29.1x earnings, slightly above Simply Wall St's fair P/E estimate …

Harvard Ave Acquisition Corporation Revenue Breakdown – NASDAQ:HAVA

ARWR Stock Clocks Best Day In Nearly 8 Months As Analyst Lifts Price Target On Plozasiran Data

Wall Street Zen Downgrades Eastern Bankshares (NASDAQ:EBC) to Sell

Wall Street Zen has downgraded Eastern Bankshares (NASDAQ:EBC) from "hold" to "sell," despite a broader consensus among other analysts for a "Moderate Buy" rating with a target price of $24.86. The company recently reported better-than-expected quarterly earnings and revenue, with shares opening at $23.63. …

Home BancShares, Inc. (NYSE:HOMB) Receives Average Rating of "Hold" from Analysts

Home BancShares, Inc. (NYSE:HOMB) has received an average "Hold" rating from eight analysts, with a consensus price target of $32.67, slightly above its current share price of $31.44. The company recently surpassed quarterly earnings and revenue expectations, reporting $0.64 EPS and $295.1 million in …

TriCo Bancshares (NASDAQ:TCBK) Receives Average Rating of "Hold" from Analysts

Analysts have issued an average "Hold" rating for TriCo Bancshares (NASDAQ:TCBK), with a 12-month average price target of $56.60. The company exceeded quarterly earnings expectations with $1.06 EPS and $111.88 million in revenue. Institutional investors hold a significant stake, and TriCo Bancshares also offers …

Wall Street Zen Upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Strong-Buy

Wall Street Zen has upgraded Regeneron Pharmaceuticals (NASDAQ:REGN) from a "buy" to a "strong-buy" rating. This upgrade follows Regeneron's strong quarterly earnings, where it surpassed analyst expectations for both EPS and revenue. Despite positive news regarding pipeline expansion and collaborations, the company faces risks …

Civista Bancshares (NASDAQ:CIVB) Share Price Crosses Above 200 Day Moving Average - What's Next?

Civista Bancshares (NASDAQ:CIVB) recently saw its stock price cross above its 200-day moving average, closing at $28.51 against an average of $25.43. The company has a "Moderate Buy" consensus rating from analysts with an average price target of $30.25, and it exceeded quarterly EPS …

NewAmsterdam Pharma (NAMS) Earnings Losses Raise The Question Of Whether The Stock Is A Bargain

Live Oak Bancshares CEO James Mahan sells $858k in company stock By Investing.com

Inovio Pharmaceuticals (NASDAQ:INO) Upgraded to "Hold" at Wall Street Zen

Wall Street Zen has upgraded Inovio Pharmaceuticals (NASDAQ:INO) from a "Sell" to a "Hold" rating, though overall analyst opinions remain mixed, with MarketBeat reporting a "Moderate Buy" consensus. The company recently exceeded earnings estimates, reporting a quarterly EPS of negative $0.07 against an expected …

Charter (CHTR) Stock Still Looks Cheap On Fresh Deal Financing News

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Charter Communications stock has endured a steep share price decline over the past few years, yet its current valuation checks still suggest the market may …

Tailwind 2.0 Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Tailwind 2.0 Acquisition Corp. announced its earnings results for the second quarter and six months ending June 30, 2026. For the second quarter, the company reported a net income of USD 1.29 million. Over the six-month period, the net income totaled USD 2.75 million.

Why Xeris Biopharma Holdings (XERS) Is Up 8.4% After Tightening 2026 Revenue Guidance And Advancing XP-8121

Talon Capital Corp. Class A Ordinary Shares (NASDAQ: TLNC) Stock Price, News & Analysis

This page provides stock price, news, and analysis for Talon Capital Corp. Class A Ordinary Shares (NASDAQ: TLNC). It includes current trading data, fundamental metrics such as market cap and volume, and links to financial statements and peer comparisons. The content is sourced from …

Hawthorn Bancshares (NASDAQ:HWBK) Raised to "Buy" at Wall Street Zen

Wall Street Zen has upgraded Hawthorn Bancshares (NASDAQ:HWBK) from "hold" to "buy," mirroring a previous upgrade by Weiss Ratings, resulting in an average analyst rating of "Buy" for the company. The financial services provider recently reported strong quarterly earnings with $1.06 EPS and $22.91 …

Eledon Pharmaceuticals (NASDAQ:ELDN) Upgraded at Wall Street Zen

Wall Street Zen upgraded Eledon Pharmaceuticals (NASDAQ:ELDN) from "strong sell" to "sell," though the broader analyst consensus remains "Hold" with a $9.67 target price. The company reported a quarterly loss of $0.27 per share, missing estimates, and its shares opened at $3.54. Institutional investors …

Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded by Wall Street Zen to Buy Rating

Wall Street Zen has upgraded Oramed Pharmaceuticals (NASDAQ:ORMP) from a "hold" to a "buy" rating, though MarketBeat's overall analyst rating for the company remains "Hold." Oramed Pharmaceuticals opened at $4.48, with a market capitalization of $186.35 million. The company recently reported a quarterly loss …

NervGen Pharma (NASDAQ:NGEN) Stock Rating Lowered by Wall Street Zen

Inflection Point Acquisition Corp. III (NASDAQ:IPCX) Rating Increased to Hold at Wall Street Zen

SAGTEC GLOBAL (SAGT) Stock Forecast and Price Target 2026 $SAGT

LB Pharmaceuticals (NASDAQ:LBRX) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded LB Pharmaceuticals (NASDAQ:LBRX) from "hold" to "sell" despite a broader analyst consensus of "Moderate Buy" with an average price target of $47.75. The company recently reported a quarterly loss of $1.71 per share, missing consensus estimates, and analysts anticipate a …

Wall Street Zen Upgrades Harrow (NASDAQ:HROW) to "Hold"

Wall Street Zen has upgraded Harrow (NASDAQ:HROW) from "sell" to "hold," though overall analyst sentiment remains a "Moderate Buy" with a target of $69.43. This comes as Harrow reported a quarterly loss that missed estimates despite slightly exceeding revenue expectations. Institutional investors hold a …

NRx Pharmaceuticals (NASDAQ:NRXP) Downgraded to "Sell" Rating by Wall Street Zen

Wall Street Zen has downgraded NRx Pharmaceuticals (NASDAQ:NRXP) from a "hold" to a "sell" rating, despite other analysts maintaining a "Moderate Buy" consensus with an average price target of $34.50. The company's stock opened at $3.27, reflecting a 2.1% drop, and recently reported a …

Wall Street Zen Upgrades Vor Biopharma (NASDAQ:VOR) to Hold

Wall Street Zen has upgraded Vor Biopharma (NASDAQ:VOR) from a "sell" to a "hold" rating. Despite this, the overall analyst consensus for Vor Biopharma remains a "Moderate Buy" with an average price target of $43.38, though the company's stock trades significantly below its 52-week …

Arbutus Biopharma (NASDAQ:ABUS) Cut to Hold at Wall Street Zen

Wall Street Zen downgraded Arbutus Biopharma (NASDAQ:ABUS) from a "buy" to a "hold" rating, though Weiss Ratings simultaneously upgraded it from "sell" to "hold." The biopharmaceutical company holds a consensus "Moderate Buy" rating and a $5.00 price target. Despite missing quarterly EPS estimates by …

Verrica Pharmaceuticals (NASDAQ:VRCA) Rating Lowered to Strong Sell at Wall Street Zen

Wall Street Zen downgraded Verrica Pharmaceuticals (NASDAQ:VRCA) from a "sell" to a "strong sell" rating. Despite this, the stock has a consensus "Hold" rating and an average target price of $14.50 from other analysts. The company recently reported a quarterly loss of $0.41 per …